Prosecution Insights
Last updated: April 19, 2026

Palleon Pharmaceuticals Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
0
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18260364 ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF ALSOMAIRY, SARAH ABDOALATIF 1646 Non-Final OA Jul 05, 2023
17624123 RECOMBINANT SIALIDASES AND METHODS OF USING THE SAME WEHBE, ANNE MARIE SABRINA 1634 Non-Final OA Dec 30, 2021
17624121 RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME BORGEEST, CHRISTINA M 1675 Non-Final OA Dec 30, 2021

Managing Palleon Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month